Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
AecorBio is an IND-stage biopharmaceutical company that has built a high-throughput peptide drug discovery platform targeting drug-resistance mechanisms in oncology, immunology, and neurology. Its lead candidate, FT-002a, is an orally available peptide co-therapeutic aimed at restoring androgen receptor inhibitor sensitivity in castration-resistant prostate cancer.
0 investors
0 investors
AEMS Corp solves viscosity problems in liquid formulations using proprietary and patented methods and an automated high-throughput, microscale lab, focusing primarily on next-generation pharmaceuticals such as high-concentration injectable biologics and siRNA therapeutics. It also formulates antimicrobial and edible sprayable coatings and other molecular systems for companies whose product development is blocked by viscosity challenges.
0 investors
0 investors
Coscien Bio develops natural-based active ingredients derived from oats — including oat beta glucan, oat avenanthramides, and oat oil — for use in skincare, health, and wellness applications. Its ingredients are supplied to consumer brands and developed for cosmeceutical, nutraceutical, and pharmaceutical products.
0 investors
Aether Therapeutics is a clinical-stage biotech company developing ATX-1209 (oral 6β-naltrexol), a first-in-class µ-opioid receptor modulator designed to reduce opioid-induced physical dependence without affecting pain relief or triggering withdrawal. Its pipeline targets chronic opioid pain dependence, opioid use disorder, neonatal opioid withdrawal syndrome, and acute/cancer pain.
0 investors
Aethl Bio is a biotech company developing wound care solutions focused on functional healing and restored skin integrity for patients with chronic wounds. Its work targets non-healing wounds such as diabetic foot ulcers, aiming to reduce recurrence, complications, and long-term care burden across the healthcare system.
0 investors
Aethlon Medical develops the Hemopurifier, a clinical-stage extracorporeal device that uses lectin-based technology to remove extracellular vesicles and enveloped viruses from blood plasma, with current clinical programs targeting patients with advanced cancer resistant to immunotherapy and potential applications in life-threatening viral infections. The company is advancing safety and feasibility trials in Australia for cancer treatment and maintains regulatory pathways for viral indications while exploring additional disease applications through preclinical research.
0 investors
ATP develops early-stage life sciences companies, focused on building new biotechnology ventures.
0 investors
0 investors